Gout in the axial skeleton.

PubWeight™: 1.62‹?› | Rank: Top 4%

🔗 View Article (PMID 19208604)

Published in J Rheumatol on February 04, 2009

Authors

Rukmini M Konatalapalli1, Paul J Demarco, James S Jelinek, Mark Murphey, Michael Gibson, Bryan Jennings, Arthur Weinstein

Author Affiliations

1: Department of Rheumatology, Washington Hospital Center, Washington, DC 20010, USA.

Articles by these authors

Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA (2005) 5.93

Antiscience and ethical concerns associated with advocacy of Lyme disease. Lancet Infect Dis (2011) 2.88

Correlates of axial gout: a cross-sectional study. J Rheumatol (2012) 2.86

Understanding why rheumatoid arthritis patient treatment preferences differ by race. Arthritis Rheum (2009) 2.66

Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum (2009) 2.58

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther (2008) 2.15

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum (2002) 1.91

Sequence and comparative analysis of the maize NB mitochondrial genome. Plant Physiol (2004) 1.83

Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials. Arthritis Rheum (2008) 1.80

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol (2013) 1.72

Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum (2002) 1.62

Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol (2008) 1.61

The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int (2010) 1.54

Atrial conduction slows immediately before the onset of human atrial fibrillation: a bi-atrial contact mapping study of transitions to atrial fibrillation. J Am Coll Cardiol (2012) 1.54

Comparisons among two fertile and three male-sterile mitochondrial genomes of maize. Genetics (2007) 1.53

Validation of self-report of rheumatoid arthritis and systemic lupus erythematosus: The Women's Health Initiative. J Rheumatol (2008) 1.47

Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Mol Cancer (2013) 1.41

Sharing Data from Cardiovascular Clinical Trials - A Proposal. N Engl J Med (2016) 1.34

Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus. J Immunol (2007) 1.22

Racial disparities in treatment preferences for rheumatoid arthritis. Med Care (2009) 1.21

Cyclic adenosine 5'-monophosphate response element modulator is responsible for the decreased expression of c-fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus. J Immunol (2004) 1.21

Imaging of periosteal osteosarcoma: radiologic-pathologic comparison. Radiology (2004) 1.12

Telangiectatic osteosarcoma: radiologic-pathologic comparison. Radiology (2003) 1.04

Fractionated stereotactic body radiation therapy in the treatment of previously-irradiated recurrent head and neck carcinoma: updated report of the University of Pittsburgh experience. Am J Clin Oncol (2010) 1.03

Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 0.99

Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum (2012) 0.98

Dilemmas in distinguishing between tumor and the posttraumatic lesion with surgical or pathologic correlation. Clin Sports Med (2013) 0.94

Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions. Appl Immunohistochem Mol Morphol (2006) 0.94

Metaphyseal and diaphyseal chondroblastomas. Skeletal Radiol (2011) 0.93

Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol (2003) 0.88

Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J (2002) 0.87

Systemic lupus erythematosus disease severity in men and women: a case-control study. J Rheumatol (2002) 0.86

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Semin Arthritis Rheum (2004) 0.85

Selective rod degeneration and partial cone inactivation characterize an iodoacetic acid model of Swine retinal degeneration. Invest Ophthalmol Vis Sci (2011) 0.85

Treatment of stent-jailed side branch stenoses with rotational atherectomy. J Invasive Cardiol (2006) 0.85

Iodoacetic acid, but not sodium iodate, creates an inducible swine model of photoreceptor damage. Exp Eye Res (2012) 0.84

Management of the antiphospholipid syndrome. Curr Rheumatol Rep (2006) 0.84

Automated neuropsychiatric measurements of information processing in fibromyalgia. Rheumatol Int (2007) 0.83

Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. Br J Clin Pharmacol (2012) 0.83

Current imaging and therapy of malignant soft tissue tumors and tumor-like lesions. Semin Musculoskelet Radiol (2013) 0.83

Posttreatment quality-of-life assessment in patients with head and neck cancer treated with intensity-modulated radiation therapy. Am J Clin Oncol (2011) 0.82

Bilateral synchronous tibial periosteal osteosarcoma with familial incidence. Skeletal Radiol (2012) 0.82

Axial (spinal) gout. Curr Rheumatol Rep (2012) 0.81

Scientific evidence and best patient care practices should guide the ethics of Lyme disease activism. J Med Ethics (2010) 0.81

Surgical experience with pseudophakic negative dysphotopsia. J Cataract Refract Surg (2012) 0.81

A multicenter randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): trial study design and rationale. J Cardiovasc Med (Hagerstown) (2010) 0.80

Musculoskeletal ultrasound objective structured clinical examination: an assessment of the test. Arthritis Care Res (Hoboken) (2014) 0.80

Osseous lesions of the pelvis and long tubular bones containing both fat and fluid-like signal intensity: an analysis of 28 patients. Eur J Radiol (2005) 0.79

Aseptic loosening rates in distal femoral endoprostheses: does stem size matter? Clin Orthop Relat Res (2012) 0.79

Von Willebrand factor, red cell fragmentation, and disease activity in systemic lupus erythematosus. HSS J (2008) 0.78

Prospective Evaluation of the St. Jude Medical Aortic Connector for Aortic-to-Autologous Vessel Graft Anastomoses. Innovations (Phila) (2005) 0.78

Low-energy femoral fractures associated with long-term bisphosphonate use in a rehabilitation setting: a case series. PM R (2010) 0.78

Calciphylaxis: a pseudo-vasculitis syndrome. Semin Arthritis Rheum (2007) 0.78

Management of early-stage esophageal neoplasia (MESEN) consensus. World J Surg (2014) 0.77

The effects of multidisciplinary therapy on positron emission tomography of the brain in fibromyalgia: a pilot study. Rheumatol Int (2007) 0.76

Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus. Curr Treat Options Oncol (2015) 0.76

IgG4-related disease. N Engl J Med (2012) 0.75

July consultation #4. J Cataract Refract Surg (2013) 0.75

Dr. Weinstein replies. J Rheumatol (2013) 0.75

Abdominal and pelvic CT for detection and volume assessment of peritoneal sarcomatosis. Tumori (2002) 0.75

Impact of multivessel disease on myocardial perfusion and survival among patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitors. Arch Cardiovasc Dis (2013) 0.75